Dysport (Botulinum Toxin) — How It Works, Benefits & Recovery — Procedure Guide, Recovery & Risks | MyMedicPlus

Dysport (abobotulinumtoxinA) is a purified, clostridium botulinum neurotoxin type A formulation approved by the US FDA and European Medicines Agency for the temporary improvement of moderate-to-severe glabellar frown lines in adults under 65 years of age, as well as therapeutic indications including cervical dystonia, upper limb spasticity, and hyperhidrosis. It works by blocking the presynaptic release of acetylcholine at the neuromuscular junction, causing temporary chemodenervation — reversible muscular paralysis — of the injected muscles. The treated muscle cannot contract for 3–5 months, smoothing the overlying dynamic wrinkle during this period. Dysport has been commercially available since the early 1990s and has one of the longest post-marketing safety records of any botulinum toxin product. It differs from onabotulinumtoxinA (Botox) and incobotulinumtoxinA (Xeomin) in its protein complex size and formulation, resulting in a slightly different diffusion profile. The Dysport unit is not interchangeable with Botox units — approximately 2.5–3 Dysport units are clinically equivalent to 1 Botox unit. Dysport has been consistently shown in randomised controlled trials to have a faster onset of action (24–48 hours versus 3–5 days for Botox) and potentially a slightly wider diffusion radius — characteristics that influence the experienced practitioner's technique and injection mapping for each patient.

Dysport is suitable for healthy adults aged 18–65 who have moderate-to-severe dynamic wrinkles — lines caused by repeated facial muscle contraction rather than static skin changes from ageing, sun damage, or volume loss. The most common cosmetic targets are: glabellar lines (vertical frown lines between the brows, the approved FDA indication), horizontal forehead lines from frontalis muscle activity, lateral canthal lines ('crow's feet' from orbicularis oculi contraction), and brow shaping by selectively weakening brow depressors. Off-label cosmetic uses include treatment of bunny lines (nasalis), lip lines (orbicularis oris), chin dimpling (mentalis), neck bands (platysmal), masseter hypertrophy (jawline slimming), and gummy smile correction. Therapeutic indications include hyperhidrosis (excessive sweating) of the axillae, palms, or feet where Dysport injection into sweat glands is highly effective; cervical dystonia (involuntary neck muscle contraction); and masseter hypertrophy causing jaw pain or bruxism. Contraindications include pregnancy, breastfeeding, allergy to botulinum toxin or excipients, neuromuscular junction disorders (myasthenia gravis, Lambert-Eaton syndrome, ALS), and active infection at proposed injection sites.

A thorough assessment precedes treatment: the practitioner evaluates facial anatomy, muscle mass, asymmetry, and the patient's movement patterns and aesthetic goals. Photographs are taken in standard views before each session. The patient is seated upright. Topical anaesthetic cream is optional — most patients tolerate the injections without any anaesthesia as the needles are ultra-fine (30–32 gauge). Dysport powder is reconstituted with 0.9% saline to the practitioner's preferred concentration, typically 2.5–4 ml per 300 IU vial. Injection sites are marked on the skin or identified by palpation of the target muscles in animation. A series of small, precise intradermal or intramuscular injections are delivered to pre-planned points: typically 3–5 injection points for glabellar lines, 3–5 for forehead, and 2–3 per side for crow's feet. For hyperhidrosis treatment, a grid pattern of approximately 15–20 injections is delivered per axilla. The entire treatment session takes 15–30 minutes including consultation, preparation, and injection. Ice packs may be applied briefly before or after injection to minimise bruising. Patients are asked to animate the treated area (frown, raise brows) immediately after injection to confirm muscle response. The total treatment session, including assessment and injection, takes approximately 15–30 minutes. Full effect is assessed at 2 weeks and any asymmetry is corrected with small top-up doses if required.

The principal benefit of Dysport is safe, reliable, and reversible improvement in dynamic facial wrinkles without surgery, downtime, or permanent commitment. The faster onset versus Botox (24–48 hours versus 3–5 days) is particularly valued by patients who want to see results before a social or professional event. A well-published Phase III clinical programme demonstrated that Dysport reduces glabellar line severity by 1–2 points on the validated 4-point Facial Wrinkle Scale in over 80% of treated patients at 2 weeks, with results maintained for 3–5 months. The treatment is repeatable indefinitely with no diminution of effect; some patients find that consistent relaxation of dynamic muscles over years reduces the depth of static resting wrinkles through habitual disuse. For therapeutic axillary hyperhidrosis, Dysport provides 6–9 months of sweat reduction exceeding 50% from baseline, substantially improving social confidence and quality of life. For cervical dystonia, Dysport is a first-line treatment evidenced in multiple randomised trials to reduce pain and abnormal head posture by clinically meaningful amounts. Jaw slimming by masseter Dysport reduces facial width and improves bruxism pain within 4–6 weeks and is maintained with 6-monthly retreatment.

Dysport has an excellent safety profile when administered by trained practitioners following anatomical principles. The most common adverse effects are injection-site bruising (5–15%), temporary mild headache (5–10%), and mild oedema at injection points, all resolving within 3–7 days. Ptosis (upper eyelid drooping) from toxin migration to the levator palpebrae muscle is the most concerning cosmetic complication, occurring in 1–5% of glabellar injections and typically resolving over 3–6 weeks; it is minimised by keeping the injection point at least 1 cm above the orbital rim and using lower doses at risk anatomical sites. Brow ptosis from excessive frontalis weakening creates a heavy brow appearance and is treated by reducing frontal injections or leaving the lateral forehead untreated on the next visit. Asymmetry at 2 weeks can be corrected with a small touch-up injection. Contraindications include known allergy to botulinum toxin or albumin (present as a stabiliser), pregnancy, and neuromuscular disease. Patients taking aminoglycoside antibiotics, calcium channel blockers, or anticoagulants may have enhanced or prolonged neuromuscular blockade or increased bruising risk and require dose adjustment or schedule consideration.

There is no downtime from Dysport injections. Patients can return to work and normal activities immediately after the appointment. The key post-injection instructions for the first 4 hours are to avoid rubbing or massaging the injected areas (which could spread toxin to adjacent muscles), avoid lying flat, and avoid strenuous exercise and excessive heat (saunas, hot yoga, vigorous gym exercise) to reduce bruising and oedema risk. Makeup may be applied gently after 4 hours. The full effect of Dysport develops over 24–48 hours and reaches its maximum at 2 weeks, when a follow-up appointment is advisable to assess results and perform any small touch-up injections if needed. Results typically last 3–5 months, with individual variation based on muscle mass, metabolism, injection technique, and sun exposure. Patients are invited to return for retreatment when movement begins to return and wrinkles re-appear, usually after 3–4 months. Long-term treatment at 3–6 monthly intervals is safe and effective; no tachyphylaxis (loss of effect) has been demonstrated in clinical studies over 7 or more years of consecutive treatments.